VA-DXC-TECHNOLOGY
DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, has been named a Leader by research firm Everest Group in its PEAK Matrix® for Life and Pensions Insurance Business Process Services/Third Party Administrators Service Provider 2022 report.
DXC provides a range of solutions to the insurance industry including business process services (BPS) and insurance software. It also serves as a licensed third-party administrator (TPA) in the U.S. and licensed broker-dealer in Canada, using its deep expertise in compliance and regulation.
The report acknowledged DXC’s position in the life insurance and pensions market with its highest designated category, noting the following:
- DXC has reaffirmed its commitment to the life and pensions (L&P) space through its strategic BPS focus, leveraging its differentiated ownership of the technology stack and especially its policy administration platforms.
-
DXC has augmented its platform-led approach and is aggressively taking its DXC Assure for Life and Wealth
platform to the market, especially for new (policy) blocks and new product launches, and is experiencing good deal momentum. Additionally, DXC Assure’s integration with both proprietary and partner/insurtech solutions further strengthens this value proposition.
-
DXC has firmed up its presence to service new/active blocks, while simultaneously focusing on large closed-block deals where it already holds significant experience and has invested in modernizing conversion methodologies.
- DXC has expanded its North American footprint through strategic BPS wins in Canada.
“Recognizing DXC as a Leader and giving us high marks for our vision and strategy reinforces the strength of our insurance services and platform-led approach,” said Ray August, president, Insurance Software and Business Process Solutions. “We will continue to invest in our life and wealth solutions, helping our customers bridge from the old to the new to better serve their customers and grow market share.”
“DXC has continued to maintain a strong position in the L&P insurance BPS/third-party administrator (TPA) market, with its large and expanding clientele, commitment to developing IT/BPS synergies through its proprietary BPaaS capabilities, and end-to-end scope of services,” said Somya Bhadola, Practice Director, Everest Group. “A balanced and customized strategic approach across new, active and closed blocks demonstrates DXC’s commitment to this market and positions it as a Leader.”
This Everest Group report assessed 20 providers based on their vision, capabilities and market impact across North America, and categorized them as Leaders, Major Contenders or Aspirants. DXC was one of only five Leaders, a position the company has held for the past 7 years when the report launched.
A custom version of the Everest Group PEAK Matrix® for Life and Pensions (L&P) Insurance BPS/TPA Service Provider 2022 is available here . DXC was also recently recognized by Everest as a Leader in its Cloud Services PEAK Matrix Assessment 2022 .
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005398/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
